Prospective Multi-centre Studies of Prognostic Factors in Castration Resistant PROState Cancer Treated With Abiraterone

Trial Profile

Prospective Multi-centre Studies of Prognostic Factors in Castration Resistant PROState Cancer Treated With Abiraterone

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms PROSABI
  • Most Recent Events

    • 12 Sep 2017 As reported in an abstract presented at the 42nd European Society for Medical Oncology Congress, currently, 48 centres are recruiting and 184 patients have been included in this study.
    • 12 Sep 2017 Planned number of patients changed from 208 to 220, as reported in an abstract presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top